Cartesian Therapeutics, Inc.

NasdaqGM RNAC

Cartesian Therapeutics, Inc. Gross Profit Margin for the Trailing 12 Months (TTM) ending September 30, 2024: 98.64%

Cartesian Therapeutics, Inc. Gross Profit Margin is 98.64% for the Trailing 12 Months (TTM) ending September 30, 2024, a 4.83% change year over year. Gross Profit Ratio is the ratio of gross profit to net sales, indicating the percentage of revenue that exceeds the cost of goods sold and reflects the efficiency of a company in managing its production or procurement and sales.
  • Cartesian Therapeutics, Inc. Gross Profit Margin for the Trailing 12 Months (TTM) ending September 30, 2023 was 94.10%, a -4.61% change year over year.
  • Cartesian Therapeutics, Inc. Gross Profit Margin for the Trailing 12 Months (TTM) ending September 30, 2022 was 98.64%, a -1.36% change year over year.
  • Cartesian Therapeutics, Inc. Gross Profit Margin for the Trailing 12 Months (TTM) ending September 30, 2021 was 100.00%, a 0.00% change year over year.
  • Cartesian Therapeutics, Inc. Gross Profit Margin for the Trailing 12 Months (TTM) ending September 30, 2020 was 100.00%, a 0.00% change year over year.
Key data
Date Gross Profit Margin Operating Income Margin EBT Margin Net Income Margin
Market news
NasdaqGM: RNAC

Cartesian Therapeutics, Inc.

CEO Dr. Carsten Brunn Ph.D.
IPO Date June 22, 2016
Location United States
Headquarters 65 Grove Street
Employees 37
Sector Health Care
Industries
Biotechnology Clinical Trials Pharmaceuticals
Description

Selecta Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the research and development of nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. The company's lead therapeutic gene therapy program is SEL-302 that is in Phase I clinical trial to enhance the treatment of methylmalonic acidemia. It is also developing biologic therapies, such as SEL-212 that is in Phase III clinical trials for the treatment of chronic refractory gout; and product candidates to treat IgA-mediated diseases, including IgA nephropathy, linear IgA bullous dermatitis, IgA pemphigus, and Henoch-Schonlein purpura. In addition, the company is developing gene therapies comprising for the treatment of pompe disease, duchenne muscular dystrophy, limb-girdle muscular dystrophy, lysosomal storage disorder, and other autoimmune diseases. Further, it develops tolerogenic therapies to treat autoimmune diseases. The company has license and collaboration agreements with Ginkgo Bioworks Holdings, Inc.; Genovis AB (publ.); Cyrus Biotechnology, Inc.; IGAN Biosciences, Inc.; Astellas Therapeutics, Inc.; Takeda Pharmaceuticals USA, Inc.; Swedish Orphan Biovitrum AB (publ.); Sarepta Therapeutics, Inc.; Asklepios Biopharmaceutical, Inc.; Massachusetts Institute of Technology; and Shenyang Sunshine Pharmaceutical Co., Ltd. Selecta Biosciences, Inc. was incorporated in 2007 and is headquartered in Watertown, Massachusetts.

StockViz Staff

January 15, 2025

Any question? Send us an email